DATA GRAPHICS | Product Development
Data Byte: FOLR1 pipeline for cancer
October 28, 2020 12:23 AM UTC
At least four antibody-drug conjugates, one antibody and two vaccines targeting FOLR1 are in development to treat cancer. The lead program is in Phase III testing for ovarian cancer.
ImmunoGen Inc. (NASDAQ:IMGN) expects data next year from the Phase III SORAYA study of ADC mirvetuximab soravtansine, and thinks accelerated approval could come in 2022. Last week, Huadong Medicine Co. Ltd. (SZSE:000963) obtained a license to the ADC covering mainland China, Hong Kong, Macau and Taiwan...